TFSA Investor: 2 Reasons to Avoid Marijuana Stocks in 2020

Canopy Growth stock and Aurora stock are the leaders in the cannabis space. However, after a massive selloff in 2019, TFSA investors are warned against investing in risky weed stocks in 2020.

| More on:
Bad apple with good apples

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The marijuana sector sizzled during the first quarter of 2019. Hysteria produced nearly 70% gains for Canopy Growth (TSX:WEED)(NYSE:CGC), Aurora Cannabis (TSX:ACB)(NYSE:ACB), and other industry players. TFSA investors were ready to bet on a sector seen to be worth US$150 billion in the next 10 to 15 years.

Sadly, the next three quarters turned out to be horrendous, not just for Canopy and Aurora but for the entire industry. The significant declines in market capitalization and sharp drops in prices are red flags. Thus, weed stocks are far too risky to place in your TFSA in 2020. You could incur large, permanent losses if you don’t heed the advice.

Tall odds

Investors who placed money on Canopy Growth in early January 2019 are losing by 45.31% today. The company reported losses of more than US$1 billion in each of the first two quarters of fiscal 2020. Although the stock’s gain year to date is 15.78%, the situation remains unstable.

Canopy is the second-largest cannabis producer at peak capacity with a presence in Canada and 16 other countries abroad. But the acknowledged industry leader is draining investors of money. The hiring of a new CEO is also no guarantee that the future will be rosy.

I need to see Canopy deal with three crucial components before I will consider investing. The company should start re-accelerating revenue growth, stabilize profit margins, and stop the bleeding or reduce net loss.

The bullish sentiment on Canopy Growth is unlikely to return anytime soon. Slowing growth and concerns over profitability remain roadblocks. Despite the predictions of some analysts that Canopy could lead a sector rally in 2020, I would instead steer clear of this weed stock.

Precarious situation

Aurora Cannabis was a big letdown last year. The largest cannabis producer at peak capacity lost over $7 billion in market value. After a series of acquisitions as far back as August 2016 and the hiring of strategic advisor Nelson Peltz, the company is facing the possibility of a massive write-down.

Since the cash position cash is not sufficient to fund many of its ongoing expansion projects, Aurora might realize only 50% of its peak production potential. The company has no choice but to stop construction projects in several of its largest cultivation facilities.

At present, only the Aurora Sun facility in Alberta is operating. The halting of construction projects meant losing 320,000 kg of run-rate peak annual output. Likewise, its Exeter facility is on selling block.

If Aurora completes the sale of this one-million-square-foot vegetable-growing greenhouse, it will eventually lose its “biggest-cannabis-producer-in-the-world” status. This depleted cannabis producer is hanging by a thread.

Picking up the pieces

Canopy Growth and Aurora Cannabis are picking up the pieces after the carnage in 2019. Either one or both might not even recover. Also, weed stocks are no longer hot choices and have no long history to show.

TFSA investors are better off building a diversified portfolio of tried-and-true stock investments this year. It will take a while before the marijuana industry in general delivers the desired results.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »